I-Mab (IMAB)
IMAB Stock Price Chart
Explore I-Mab interactive price chart. Choose custom timeframes to analyze IMAB price movements and trends.
IMAB Company Profile
Discover essential business fundamentals and corporate details for I-Mab (IMAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Jan 2020
Employees
32.00
Website
https://www.i-mabbiopharma.comCEO
Xi-Yong Fu
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
IMAB Financial Timeline
Browse a chronological timeline of I-Mab corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 1 Apr 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.07.
Earnings released on 20 Aug 2025
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%.
Earnings released on 15 May 2025
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%.
Earnings released on 3 Apr 2025
EPS came in at -$0.00 surpassing the estimated -$0.01 by +71.97%.
Earnings released on 14 Nov 2024
EPS came in at -$0.25 falling short of the estimated -$0.16 by -56.25%.
Earnings released on 28 Aug 2024
EPS came in at -$0.07 surpassing the estimated -$0.51 by +86.27%.
Earnings released on 30 Apr 2024
EPS came in at -$0.26 , while revenue for the quarter reached $563.99K .
Earnings released on 29 Mar 2024
EPS came in at $0.02 surpassing the estimated -$0.10 by +116.17%, while revenue for the quarter reached $164.16K .
Earnings released on 30 Sept 2023
EPS came in at -$0.25 , while revenue for the quarter reached $546.77K .
Earnings released on 17 Aug 2023
EPS came in at -$0.28 falling short of the estimated -$0.26 by -7.23%, while revenue for the quarter reached $1.36M , beating expectations by +41.23%.
Earnings released on 1 May 2023
EPS came in at -$0.56 , while revenue for the quarter reached -$19.97M .
Earnings released on 31 Mar 2023
EPS came in at -$0.29 , while revenue for the quarter reached $1.43M .
Earnings released on 10 Nov 2022
EPS came in at -$0.41 , while revenue for the quarter reached $3.87M .
Earnings released on 30 Aug 2022
EPS came in at -$0.54 falling short of the estimated -$0.16 by -235.01%, while revenue for the quarter reached -$19.14M , missing expectations by -855.48%.
Earnings released on 29 Mar 2022
EPS came in at -$0.44 falling short of the estimated -$0.34 by -28.30%, while revenue for the quarter reached $4.08M , missing expectations by -66.33%.
Earnings released on 12 Nov 2021
EPS came in at -$0.54 , while revenue for the quarter reached $5.44M .
Earnings released on 28 Apr 2021
EPS came in at $0.98 , while revenue for the quarter reached $236.32M .
Earnings released on 5 Feb 2021
EPS came in at $0.01 surpassing the estimated -$0.09 by +114.92%.
IMAB Stock Performance
Access detailed IMAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.